Because every
life counts.
Because every
life counts.
Saving lives and improving quality of life through personalized phage therapy.
Saving lives and improving quality of life through
personalized phage therapy.
Because every life counts.
Antimicrobial resistance (AMR) is classified by the WHO as one of the greatest global health challenges of our time. More and more bacterial infections no longer respond to available antibiotics.
Bacteriophages — viruses that exclusively infect bacteria — are a biological approach studied for decades that is now receiving broad scientific attention again in the context of AMR. Delta G Avaris researches and develops the advancement of this approach.
Our ambition is to combine scientific excellence with industrial quality standards. GMP-certified production processes, documented supply chains, and a clean evidence base are not optional for us — they are prerequisites.
ESKAPE — six pathogens,
one global priority.
The WHO identifies the ESKAPE group as a priority threat. Together they cause the majority of severe nosocomial infections and increasingly evade established antibiotic therapy. Our research targets these pathogens specifically.
Our goal is to combat antimicrobial resistance using a holistic, personalized phage therapy approach that covers the entire pipeline from analysis to application.
Our goal is to combat antimicrobial resistance using a holistic, personalized phage therapy approach that covers the entire pipeline from analysis to application.
Press & News.
Further professional
information.
Scientific data, product information, and study documents are exclusively available to healthcare professionals in the restricted area.